Artelo Bio CAReS trial on track; board approves 2022 goals, cuts quorum to 35%

ARTELO BIOSCIENCES, INC.

CEO Gorgas eligible for 2022 bonus based on goals: clinical (40%), pre-clinical (35%), financial (25%).
Bylaws amended to reduce shareholder quorum requirement to 35%.
CAReS Phase 1 enrollment for ART27.13 expected to complete by end of Q1 2022.
Phase 1 results to inform dose selection within ~6 weeks of last patient; optional fourth cohort possible.
Company currently sees no significant COVID-19 impact on trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.